Arbutus Biopharma Corp. (ABUS)

4.50 +0.02 (+0.45%) USD  |  NASDAQ  |  Apr 06, 13:16
More

Arbutus Biopharma Revenue Estimates for Current Fiscal Year

Revenue Estimates for Current Fiscal Year Chart

View Revenue Estimates for Current Fiscal Year for ABUS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Revenue Estimates for Current Fiscal Year Chart
Start Trial

Historical Data

View Historical Data
Start Trial

Revenue Estimates for Current Fiscal Year Range, Past 5 Years

View Revenue Estimates for Current Fiscal Year Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Revenue Estimates for Current Fiscal Year Benchmarks

View Revenue Estimates for Current Fiscal Year Benchmarks
Start Trial
Moderna, Inc. Upgrade
Merck & Co., Inc. Upgrade
Pfizer Inc. Upgrade
ACADIA Pharmaceuticals, Inc. Upgrade
Alnylam Pharmaceuticals, Inc. Upgrade

Revenue Estimates for Current Fiscal Year Related Metrics

Revenue Estimates for Current Quarter Upgrade
Revenue Estimates for Next Quarter Upgrade
Revenue Estimates for Next Fiscal Year Upgrade
EPS Estimates for Current Quarter Upgrade
EPS Estimates for Next Quarter Upgrade
EPS Estimates for Current Fiscal Year Upgrade
EPS Estimates for Next Fiscal Year Upgrade